sr141716 has been researched along with Disease Exacerbation in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brown, MW; Deanfield, JE; Després, JP; Job, B; Kastelein, JJ; Nissen, SE; O'Leary, DH; Reuwer, AQ; Visseren, FL; Zabbatino, SM; Zhou, R | 1 |
| Ditrói, K; Kleiner, D | 1 |
| Deveaux, V; Grenard, P; Julien, B; Ledent, C; Li, L; Lotersztajn, S; Mallat, A; Serriere-Lanneau, V; Teixeira-Clerc, F; Tran Van Nhieu, J | 1 |
| Deveaux, V; Hezode, C; Lotersztajn, S; Mallat, A; Teixeira-Clerc, F; Tran van Nhieu, J | 1 |
| Bhatt, DL; Cannon, CP; Deanfield, JE; Després, JP; Gaudin, C; Hu, B; Job, B; Kapadia, S; Kastelein, JJ; Lincoff, AM; Nicholls, SJ; Nissen, SE; Rodés-Cabau, J; Ruzyllo, W; Steinhubl, SR; Tuzcu, EM; Wolski, K; Yasin, M | 1 |
1 review(s) available for sr141716 and Disease Exacerbation
| Article | Year |
|---|---|
[The potential use of cannabidiol in the therapy of metabolic syndrome].
Topics: Adipocytes; Appetite Depressants; Atherosclerosis; Cannabidiol; Cannabinoid Receptor Antagonists; Disease Progression; Humans; Hyperphagia; Ischemia; Metabolic Syndrome; Obesity; Piperidines; PPAR gamma; Pyrazoles; Rimonabant | 2012 |
2 trial(s) available for sr141716 and Disease Exacerbation
| Article | Year |
|---|---|
Effect of rimonabant on carotid intima-media thickness (CIMT) progression in patients with abdominal obesity and metabolic syndrome: the AUDITOR Trial.
Topics: Anti-Obesity Agents; Canada; Carotid Arteries; Carotid Artery Diseases; Chi-Square Distribution; Disease Progression; Double-Blind Method; Europe; Female; Humans; Kaplan-Meier Estimate; Male; Metabolic Syndrome; Obesity, Abdominal; Piperidines; Placebo Effect; Prospective Studies; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Time Factors; Treatment Outcome; Tunica Intima; Tunica Media; Ultrasonography; United States; Waist Circumference; Weight Loss | 2011 |
Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial.
Topics: Aged; Atherosclerosis; Coronary Artery Disease; Coronary Vessels; Diet, Reducing; Disease Progression; Double-Blind Method; Female; Humans; Male; Metabolic Syndrome; Middle Aged; Obesity; Piperidines; Prospective Studies; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Ultrasonography, Interventional | 2008 |
2 other study(ies) available for sr141716 and Disease Exacerbation
| Article | Year |
|---|---|
CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis.
Topics: Animals; Cannabinoid Receptor Modulators; Disease Progression; Female; Humans; Liver; Liver Cirrhosis; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Retrospective Studies; Rimonabant; Transforming Growth Factor beta; Transforming Growth Factor beta1 | 2006 |
[Endocannabinoids: therapeutic perspectives in chronic liver diseases].
Topics: Animals; Appetite Depressants; Cannabinoid Receptor Modulators; Cannabinoids; Chronic Disease; Disease Models, Animal; Disease Progression; Endocannabinoids; Fatty Liver; Glycolysis; Hepatitis C, Chronic; Hepatocytes; Humans; Hypertension, Portal; Lipogenesis; Liver; Liver Cirrhosis; Liver Diseases; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Rimonabant | 2007 |